Lilly Cut an Obesity Drug -- but the Move Shows How High Its Bar Has Become
By newsfeedback@fool.com (Reuben Gregg Brewer)
Read original article on Motley FoolEli Lilly (NYSE: LLY) has seen huge success in the GLP-1 weight-loss drug space with Mounjaro and Zepbound. Although it was second to market after Novo Nordisk (NYSE: NVO) in the GLP-1 space, better patient outcomes and Novo Nordisk's inability to keep up with demand enabled Eli Lilly to take the industry lead. But there's a longer-term problem here, and Eli Lilly is attempting to get ahead of it, even if it means some new drug candidates fall by the wayside. Here's what you need to know.
Eli Lilly recently stopped its development of a new GLP-1 weight-loss drug. The company had expectations for the drug's efficacy, and it didn't live up to them. It's unfortunate, but it happens. Investors shouldn't take this one event and blow it out of proportion.
This story was originally published on Motley Fool. DennTech aggregates headlines from top crypto publications to keep traders informed.
Read full article on Motley Fool